XOLARIS
Dec 01 2020
To gain a better understanding of disease progression over time in male subjects with X-linked retinitis pigmentosa (XLRP).
Read MoreAGTC A3
Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene Sponsor: Applied Genetic Technologies Corp…
Read MoreAGTC B3
Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene Sponsor: Applied Genetic Technologies Corp visit…
Read MoreNIGHT
Sep 30 2020
Natural History of the Progression of Choroideremia Study (NIGHT) Sponsor: NightstaRx Ltd, a Biogen Company CLINICALTRIALS.GOV
Read MoreSTAR
Sep 30 2020
A Randomized, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) (STAR) Sponsor: NightstaRx…
Read MoreSOLSTICE
Sep 30 2020
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Treated Previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study (SOLSTICE)
Read More
Vision Driven. The Chad Mayfield Story.
Dec 07 2018
If you’d had the good fortune to know Chad Mayfield as a kid, you’d have thought it quite reasonable, even probable, that he would grow up to play third base in the big leagues…
Read More